Recently Published GRAS Notices and FDA Letters
For a full listing of notices and response letters, please visit the inventory database.
| GRN No. | Substance | GRAS Notice | FDA Letter |
|---|---|---|---|
| 1162 | Fungal oil (≥38% arachidonic acid (ARA)) from Mortierella alpina FJRK-MA01 | GRN 1162 (PDF 13.5 MB) |
FDA ceased to evaluate (PDF 159 KB) |
| 1156 | Algal oil (≥35% docosahexaenoic acid from Schizochytrium sp. FJRK-SCH3 | GRN 1156 (PDF 7.9 MB) |
FDA ceased to evaluate (PDF 199 KB) |
| 1142 | Brazzein produced by Komagataella phaffii expressing a gene encoding for brazzein from Pentadiplandra brazzeana | GRN 1142 with Amendments (PDF 7.0 MB) |
FDA has no questions (PDF 257 KB) |
| 1137 | Protein-sucrose | GRN 1137 with Amendments (PDF 9.4 MB) |
FDA has no questions (PDF 188 KB) |
| 1136 | Dry whole goat milk | GRN 1136 with Amendments (PDF 8.6 MB) |
FDA has no questions (PDF 267 KB) |
| 1135 | Galacto-oligosaccharides | GRN 1135 with Amendments (PDF 3.8 MB) |
FDA ceased to evaluate (PDF 133 KB) |
| 1133 | Resistant dextrin from corn | GRN 1133 (PDF 4.4 MB) |
|
| 1132 | Hydrolyzed-poultry-protein | GRN 1132 (PDF 6.5 MB) |
|
| 1131 | Bacillus subtilis ATCC BS50 PTA-127287 | GRN 1131 with Amendments (PDF 6.2 MB) |
FDA has no questions (PDF 267 KB) |
| 1129 | Heat-killed Clostridium tyrobutyricum strain | GRN 1129 (PDF 84.3 MB) |
|
| 1126 | Calcium acetate | GRN 1126 (PDF 3.9 MB) |
|
| 1124 | B-glucans from Hericium erinaceus strain BCRC 35669 | GRN 1124 with Amendments (PDF 6.9 MB) |
FDA ceased to evaluate (PDF 206 KB) |
| 1123 | Sucrose fatty acid esters | GRN 1123 with Amendments (PDF 6.6 MB) |
FDA has no questions (PDF 214 KB) |
| 1121 | Fructanase enzyme preparation produced by Trichoderma reesei expressing the gene encoding fructanase from Lactobacillus sp. | GRN 1121 (PDF 4.2 MB) |
|
| 1120 | Alpha-Galactosidase Enzyme preparation produced by Aspergillus niger | GRN 1120 (PDF 3.3 MB) |
|
| 1119 | Olea europaea L. leaf extract | GRN 1119 (PDF 2.6 MB) |
|
| 1118 | Pyrroloquinoline quinone disodium salt | GRN 1118 with Amendments (PDF 7.4 MB) |
FDA has no questions (PDF 356 KB) |
| 1117 | Mycelial biomass from Neurospora crassa | GRN 1117 (PDF 7.1 MB) |
|
| 1116 | Shea stearin | GRN 1116 Part 1 (GRN Parts 1 - 4) (PDF 13 MB) GRN 1116 Part 2 (GRN Parts 5 - 7) (PDF 14 MB) GRN 1116 Part 3 (GRN Appendix A and B) (PDF 8 MB) GRN 1116 Part 4 (GRN Appendix C) (PDF 14 MB) GRN 1116 Part 5 (GRN Appendix C Cont.) (PDF 13 MB) GRN 1116 Part 6 (GRN Appendix D - H) (PDF 9 MB) |
|
| 1115 | Fungal oil (≥40% arachidonic acid (ARA)) from Mortierella alpina strain AF | GRN 1115 with Amendments (PDF 13.1 MB) |
FDA has no questions (PDF 256 KB) |
| 1114 | Bifodobacterium breve DSM 33444 | GRN 1114 with Amendments (PDF 4.7 MB) |
FDA has no questions (PDF 141 KB) |
| 1113 | Lactobacillus-plantarum-NCIMB-30562 | GRN 1113 with Amendments (PDF 3.2 MB) |
FDA has no questions (PDF 423 KB) |
| 1111 | Endo-1, 4-B-xylanase enzyme preparation produced by Bacillus subtilis expressing the gene encoding xylanase from B. subtilis | GRN 1111 (PDF 3 MB) |
|
| 1110 | Polygalacturonase enzyme preparation produced by Trichoderma reesei expressing a gene encoding a polygalacturonase from Aspergillus kawachii | GRN 1110 (PDF 4 MB) |
|
| 1109 | B-agarase enzyme preparation produced by Streptomyces coelicolor | GRN 1109 (PDF 9.4 MB) |
|
| 1108 | Lactiplantibacillus plantarum strain MCC 0537 | GRN 1108 with Amendments (PDF 5.7 MB) |
FDA has no questions (PDF 209 KB) |
| 1107 | Bifidobacterium longum subsp. infantis strain LMG 11588 | GRN 1107 with Amendments (PDF 2.8 MB) |
FDA has no questions (PDF 241 KB) |
| 1106 | Rebaudioside I obtained by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni (rebaudioside I) | GRN 1106 with Amendments (PDF 4.8 MB) |
FDA has no questions (PDF 277 KB) |
| 1105 | Polyglycerol polyricinoleic acid | GRN 1105 with Amendments (PDF 7.32 MB) |
FDA has no questions (PDF 225 KB) |
| 1104 | Egg-white protein produced by Komagataella phaffii ATCC GSD-1235 | GRN 1104 with Amendments (PDF 5.2 MB) |
FDA has no questions (PDF 264 KB) |
| 1102 | Invertase enzyme preparation produced by Trichoderma reesei expressing a gene for invertase from Aspergillus niger | GRN 1102 (PDF 6.4 MB) |
|
| 1101 | Dried biomass of Chlamydomonas reinhardtii strain TAl114 | GRN 1101 (PDF 4 MB) |
FDA ceased to evaluate (PDF 161 KB) |
| 1100 | Fractioned whey protein concentrate containing 41% alpha-lactalbumin | GRN 1100 with Amendments (PDF 2.8 MB) |
FDA has no questions (PDF 259 KB) |
| 1098 | Chickpea protein concentrate | GRN 1098 (PDF 11.4 MB) |
|
| 1099 | 3-fucosyllactose | GRN 1099 with Amendments (PDF 2.6 MB) |
FDA has no questions (PDF 292 KB) |
| 1097 | Maltogenic alpha-amylase enzyme preparation produced by Escherichia coli expressing a gene encoding a maltogenic alpha-amylase from Geobacillus stearothermophilus | GRN 1097 (PDF 7.3 MB) |
|
| 1096 | Saccharomyces cerevisiae strain OYR-243 | GRN 1096 with Amendments (PDF 13.1 MB) |
FDA has no questions (PDF 212 KB) |
| 1095 | Baillus subtilis strain ATCC AAN000002 spore preparation | GRN 1095 with Amendments (PDF 7.4 MB) |
FDA has no questions (PDF 286 KB) |
| 1093 | Lacticaseibacillus rhamnosus IDCC 3201 | GRN 1093 with Amendments (PDF 5.5 MB) |
FDA has no questions (PDF 265 KB) |
| 1092 | Bifidobacterium animalis subsp. lactis IDCC 4301 | GRN 1092 with Amendments (PDF 20.2 MB) |
FDA has no questions (PDF 267 KB) |
| 1091 | 2'-fucosyllactose | GRN 1091 (PDF 1.8 MB) |
|
| 1090 | Bifidobacterium bifidum strain NITE BP-31 | GRN 1090 with Amendments (PDF 9.3 MB) |
FDA has no questions (PDF 209 KB) |
| 1089 | Lactobacillus gasseri strain NCIMB 30370 | GRN 1089 with Amendments (PDF 6.4 MB) |
FDA has no questions (PDF 244 KB) |
| 1088 | Lactococcus lactis strain KCTC 11865BP | GRN 1088 (PDF 4.6 MB) |
|
| 1087 | Streptococcus thermophilus strain KCTC 11870BP | GRN 1087 (PDF 5.9 MB) |
|
| 1086 | Lactobacillus plantarium CBT LP3 | GRN 1086 (PDF 5 MB) |
FDA has no questions (PDF 291 KB) |
| 1085 | Lactobacillus casei strain KCTC 12398BP | GRN 1085 (PDF 2.9 MB) |
FDA has no questions (PDF 313 KB) |
| 1084 | Lactobacillus rhamnosus CBT LR5 | GRN 1084 with Amendments (PDF 9.8 MB) |
FDA has no questions (PDF 247 KB) |
| 1083 | Lactobacillus acidophilus CBT LA1 | GRN 1083 (PDF 7.3 MB) |
|
| 1082 | Bifidobacterium lactis strain KCTC 11904BP | GRN 1082 with Amendments (PDF 10.1 MB) |
FDA has no questions (PDF 267 KB) |
| 1081 | Bifidobacterium infantis strain KCTC 11859BP | GRN 1081 (PDF 6.8 MB) |
|
| 1080 | Bifidobacterium breve strain KCTC 12201BP | GRN 1080 (PDF 12.7 MB) |
|
| 1079 | Bifidobacterium bifidum strain KCTC 12200BP | GRN 1079 Part 1 (PDF 7.5 MB) GRN 1079 Part 2 Amendments (PDF 13.3 MB) GRN 1079 Part 3 Amendments (PDF 6.8 MB) |
FDA has no questions (PDF 240 KB) |
| 1078 | Bifidobacterium bifidum strain KCTC 12199BP | GRN 1078 (PDF 3.7 MB) |
|
| 1077 | Oat polar lipid extract | GRN 1077 (PDF 5.9 MB) |
|
| 1076 | Galacto-oligosaccharides | GRN 1076 with Amendments (PDF 4 MB) |
FDA has no questions (PDF 245 KB) |
| 1075 | 6'-sialyllactose sodium salt | GRN 1075 with Amendments (PDF 6.3 MB) |
FDA has no questions (PDF 286 KB) |
| 1074 | 3'-sialyllactose sodium salt | GRN 1074 with Amendments (PDF 7 MB) |
FDA has no questions (PDF 383 KB) |
| 1073 | Corn bran arabinoxylan | GRN 1073 (PDF 10.8 MB) |
|
| 1072 | Lemnaceae fiber | GRN 1072 with Amendments (PDF 16 MB) |
FDA ceased to evaluate (PDF 229 KB) |
| 1071 | Glucose oxidase enzyme preparation produced by Saccharomyces cerevisiae expressing a gene encoding glucose oxidase from Aspergillus niger | GRN 1071 (PDF 2.3 MB) |
|
| 1070 | Preparations containing six bacteriophages (phage) specific to Salmonella enterica | GRN 1070 with Amendments (PDF 7.3 MB) |
FDA has no questions (PDF 279 KB) |
| 1069 | Corn protein | GRN 1069 (PDF 8.2 MB) |
|
| 1068 | Lacto-N-tetraose | GRN 1068 with Amendments (PDF 2.0 MB) |
FDA has no questions (PDF 302 KB) |
| 1067 | Lacto-N-neotetraose | GRN 1067 with Amendments (PDF 7.6 MB) |
FDA has no questions (PDF 306 KB) |
| 1066 | Carnobacterium divergens strain M35 | GRN 1066 (PDF 3 MB) |
|
| 1065 | Anaerobutyricum soehngenii CH106 | GRN 1065 with Amendments (PDF 7.4 MB) |
FDA has no questions (PDF 222 KB) |
| 1064 | Pomegranate extract | GRN 1064 (PDF 5 MB) |
|
| 1063 | Weissella cibaria CMU | GRN 1063 (PDF 27.0 MB) |
|
| 1062 | Saccharomyces cerevisiae strain OYR-185 | GRN 1062 with Amendments (PDF 19.2 MB) |
FDA has no questions (PDF 207 KB) |
| 1060 | 2'-fucosyllactose | GRN 1060 with Amendments (PDF 9.9 MB) |
FDA has no questions (PDF 333 KB) |
| 1059 | Lacto-N-neotetraose | GRN 1059 with Amendments (PDF 2.8 MB) |
FDA has no questions (PDF 288 KB) |
| 1058 | Polyvinyl alcohol | GRN 1058 with Amendments (PDF 15.8 MB) |
FDA has no questions (PDF 283 KB) |
| 1057 | D-psicose | GRN 1057 with Amendments (PDF 13.8 MB) |
FDA has no questions (PDF 298 KB) |
| 1056 | B-lactoglobulin produced by Komagataella phaffii strain "yRMK-66" | GRN 1056 with Amendments (PDF 8.2 MB) |
FDA has no questions (PDF 291 KB) |
| 1055 | Xylanase enzyme preparation produced by Bacillus licheniformis strain expressing the xylanase gene from Chryseobacterium | GRN 1055 with Amendments (PDF 3.0 MB) |
FDA has no questions (PDF 265 KB) |
| 1054 | Glucose oxidase enzyme preparation produced by Aspergillus niger expressing the gene encoding glucose oxidase from A. niger | GRN 1054 with Amendments (PDF 5.1 MB) |
FDA has no questions (PDF 270 KB) |
| 1053 | 6'-sialyllactose sodium salt | GRN 1053 with Amendments (PDF 15.4 MB) |
FDA has no questions (PDF 266 KB) |
| 1052 | 3'-sialyllactose sodium salt | GRN 1052 with Amendments (PDF 12.3 MB) |
FDA has no questions (PDF 292 KB) |
| 1051 | 2'-Fucosyllactose | GRN 1051 (PDF 18 MB) GRN 1051 Part 2 Amendments (PDF 4.9 MB) |
FDA has no questions (PDF 298 KB) |
| 1050 | High 2-palmitic acid vegetable oil | GRN 1050 with Amendments (PDF 7.2 MB) |
FDA ceased to evaluate (PDF 175 KB) |
| 1049 | Medium-chain triacylglycerols | GRN 1049 with Amendments (PDF 10.8 MB) |
FDA has no questions (PDF 249 KB) |
| 1047 | Lipase produced by Saccharomyces cerevisiae | GRN 1047 (PDF 3.0 MB) |
|
| 1046 | Collagenase enzyme preparation from genetically modified Streptomyces violaceoruber expressing a collagenase gene | GRN 1046 with Amendments (PDF 8.9 MB) |
FDA has no questions (PDF 219 KB) |
| 1045 | Resistant dextrin from tapioca | GRN 1045 with Amendments (PDF 5.1 MB) |
FDA has no questions (in PDF, 250 KB) |
| 1044 | Calcium disodium ethylenediaminetetraacetic acid | GRN 1044 (PDF 4.9 MB) |
FDA ceased to evaluate (PDF 118 KB) |
| 1043 | Cetylated fatty acids | GRN 1043 with Amendments (PDF 6.9 MB) |
FDA has no questions (PDF 189 KB) |
| 1042 | Menaquinone-7 derived from a specific strain of Bacillus subtilis natto | GRN 1042 (PDF 17 MB) |
FDA ceased to evaluate (PDF 188 KB) |
| 1041 | Dry whole milk | GRN 1041 with Amendments (PDF 2.0 MB) |
FDA has no questions (PDF 152 KB) |
| 1040 | 2'-fucosyllactose | GRN 1040 (PDF 5.7 MB) |
FDA ceased to evaluate (PDF 116 KB) |
| 1039 | Lactase enzyme preparation produced by Aspergillus oryzae | GRN 1039 (PDF 2.9 MB) |
|
| 1038 | Preparation containing six bacteriophages (phage) specific to Salmonella enterica spp. serovars | GRN 1038 with Amendments (PDF 20.4 MB) |
FDA has no questions (PDF 333 KB) |
| 1037 | 3-fucosyllactose | GRN 1037 with Amendments (PDF 7 MB) |
FDA has no questions (PDF 287 KB) |
| 1036 | Complexation products of iron with sodium citrate | GRN 1036 with Amendments (PDF 1.2 MB) |
FDA has no questions (PDF 285 KB) |
| 1035 | Lacto-N-fucopentaose l with 2'-fucosyllactose | GRN 1035 with Amendments (PDF 14.9 MB) |
FDA has no questions (PDF 288 KB) Correction Letter (PDF 138 KB) |
| 1034 | 2'-fucosyllactose | GRN 1034 with Amendments (PDF 3 MB) |
FDA has no questions (PDF 258 KB) |
| 1033 | Hydrolyzed Saccharomyces cerevisiae | GRN 1033 (PDF 2.0 MB) |
|
| 1032 | D-&beta-hydroxybutyrate | GRN 1032 with Amendments (PDF 7.08 MB) |
FDA has no questions (PDF 214 KB) |
| 1031 | Barley and rice protein hydrolysate | GRN 1031 with Amendments (PDF 4 MB) |
FDA has no questions (PDF 219 KB) |
| 1030 | Cellulase enzyme preparation produced by Aspergillus niger genetically engineered to express a cellulase gene from Trichoderma reesei | GRN 1030 with Amendments (PDF 8 MB) |
FDA has no questions (PDF 286 KB) |
| 1029 | D-psicose | GRN 1029 with Amendments (PDF 11.1 MB) |
FDA has no questions (PDF 255 KB) |
| 1028 | Metschnikowia pulcherrima DANMET-A and M. fructicola DANMET-B | GRN 1028 (PDF 3.2 MB) |
|
| 1027 | Miracle fruit (Synsepalum dulcificum) powder | GRN 1027 (PDF 2.3 MB) |
FDA ceased to evaluate (PDF 137 KB) |
| 1026 | Silk fibroin derived from Bombyx mori cocoons |
GRN 1026 Part 1 with Appx A-D |
FDA has no questions (PDF 185 KB) |
| 1025 | Pepsin A enzyme preparation produced by Pichia pastoris to overexpress the gene pepsin A | GRN 1025 with Amendments (PDF 2.9 MB) |
FDA has no questions (PDF 318 KB) |
| 1024 | D-psicose | GRN 1024 with Amendments (PDF 15.6 MB) |
FDA has no questions (PDF 253 KB) |
| 1023 | Monosodium L-5-methyltetrahydrofolate | GRN 1023 Part 1 (PDF 17 MB) GRN 1023 Part 2 with Amendments (PDF 20 MB) |
FDA ceased to evaluate (PDF 85 KB) |
| 1022 | Streptococcus salivarius DB-B5 |
GRN 1022 with Amendments |
FDA has no questions (PDF 177 KB) |
| 1021 | Transglutaminase enzyme preparation produced by Streptomyces mobaraensis strain M2020197 | GRN 1021 with Amendments (PDF 7.3 MB) |
FDA has no questions (PDF 395 KB) |
| 1020 | Protein from Helianthus annuus (sunflower protein) | GRN 1020 with Amendments (PDF 4.5 MB) |
FDA ceased to evaluate (PDF 101 KB) |
| 1019 | Agave mixed fructans from Agave tequilana Weber var. azul | GRN 1019 with Amendments (PDF 3.5 MB) |
FDA has no questions (in PDF, 271 KB) |
| 1018 | Carbon monoxide | GRN 1018 with Amendments (PDF 4.2 MB) |
FDA has no questions (PDF 254 KB) |
| 1017 | Lacto-N-tetraose | GRN 1017 (PDF 3.3 MB) |
FDA has no questions (PDF 245 KB) |
| 1016 | 6’-sialyllactose sodium salt | GRN 1016 with Amendments (PDF 3.9 MB) |
FDA has no questions (PDF 237 KB) |
| 1015 | 3’-sialyllactose sodium salt | GRN 1015 with Amendments (PDF 4.0 MB) |
FDA has no questions (PDF 234 KB) |
| 1014 | 2'-fucosyllactose | GRN 1014 with Amendments (PDF 5.5 MB) |
FDA has no questions (PDF 295 KB) |
| 1013 | Lactobacillus rhamnosus DSM 33156 | GRN 1013 (PDF 18.0 MB) |
FDA has no questions (PDF 310 KB) |
| 1012 | Powdered sap from Angelica keiskei (ashitaba) containing 8% chalcones (ashitaba sap) | GRN 1012 (PDF 5.1 MB) |
FDA ceased to evaluate (PDF 107 KB) |
| 1011 | Alpha-amylase enzyme preparation produced by Bacillus subtilis strain AR-651 expressing the gene encoding alpha-amylase from Thermoactinomyces vulgaris | GRN 1011 with Amendments (PDF 2.6 MB) |
FDA has no questions (PDF 294 KB) |
| 1010 | Rebaudioside M obtained by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) | GRN 1010 (PDF 5.1 MB) |
FDA has no questions (PDF 411 KB) |
| 1009 | Water-soluble palm fruit extract | GRN 1009 (PDF 1.0 MB) |
FDA ceased to evaluate (PDF 128 KB) |
| 1008 | Algal oil (≥45% docosahexaenoic acid) from Aurantiochytrium limacinum TKD-1 | GRN 1008 with Amendments (PDF 2.7 MB) |
FDA has no questions (PDF 165 KB) |
| 1007 | Bacillus-subtilis Strain R0179 | GRN 1007 Part 1 (PDF 15.2 MB) GRN 1007 Part 2 (PDF 12.82 MB) GRN 1007 Part 3 (PDF 12.93 MB) GRN 1007 Part 4 (PDF 11.84 MB) GRN 1007 Part 5 (PDF 17.96 MB) GRN 1007 Part 6 (PDF 11.01 MB) GRN 1007 Part 7 (PDF 6.04 MB) |
FDA ceased to evaluate (PDF 184 KB) |
| 1006 | Short-chain fructooligosaccharides | GRN 1006 with Amendments (PDF 837 KB) |
FDA has no questions (PDF 177 KB) |
| 1005 | Beta Lactoglobulin from cow milk | GRN 1005 with Amendments (PDF 4.9 MB) |
FDA ceased to evaluate (PDF 93 KB) |
| 1004 | Maltosyltrehalose syrup | GRN 1004 with Amendments (PDF 13 MB) |
FDA ceased to evaluate (PDF 84 KB) |
| 1003 | Bifidobacterium longum subsp. infantis M-63 | GRN 1003 with Amendments (PDF 2.2 MB) |
FDA has no questions (PDF 74 KB) |
| 1002 | Bifidobacterium breve strain MCC1274 | GRN 1002 with Amendments (PDF 3.6 MB) |
FDA has no questions (PDF 221 KB) |
| 1001 | Myoglobin preparation from a strain of Pichia pastoris expressing the myoglobin gene from Bos taurus | GRN 1001 with Amendments (PDF 14.6 MB) |
FDA has no questions (PDF 374 KB) |
| 1000 | Phycocyanin-rich extract of Galdieria sulphuraria (G. sulphuraria strain "FCC3424") | GRN 1000 (PDF 2 MB) |
FDA ceased to evaluate (PDF 160 KB) |
| 999 | Enzyme-modified steviol glycosides | GRN 999 (PDF 5.2 MB) |
FDA has no questions (PDF 171 kB) |
| 998 | Corn bran arabinoxylan | GRN 998 (PDF 3.9 MB) |
FDA ceased to evaluate (PDF 100 KB) |
| 997 | Chitosan and beta-1, 3-glucans from white button mushrooms (Agaricus bisporus) | GRN 997 (PDF 4.4 MB) GRN 997 Amendments (PDF 2.4 MB) |
FDA has no questions (PDF 140 kB) |
| 996 | Synthetic amorphous silica | GRN 996 with Amendments (PDF 4.6 MB) |
FDA has no questions (PDF 137 KB) |
| 995 | beta-glucans from Antrodia cinnamomea strain ATCC 200183 | GRN 995 with Amendments (PDF 5.4 MB) |
FDA has no questions (PDF 162 KB) |
| 994 | Miracle fruit (Synsepalum dulcificum) in pulp, powder or protein forms | GRN 994 (PDF 2.0 MB) |
FDA ceased to evaluate (PDF 140 KB) |
| 993 | L-carnitine-L-tartrate | GRN 993 with Amendments (PDF 3.0 MB) |
FDA has no questions (PDF 149 KB) |
| 992 | White mulberry (Morus alba Linn) leaf extract | GRN 992 with Amendments | FDA ceased to evaluate (PDF 96 kB) |
| 991 | Chitonase enzyme preparation produced by Bacillus subtilis | GRN 991 with Amendments (PDF 14.3 MB) |
FDA has no questions (PDF 225 KB) |
| 990 | Short-chain fructooligosaccharides | GRN 990 with Amendments (PDF 9.0 MB) |
FDA has no questions (PDF 118 KB) |
| 989 | Bacillus subtilis expressing a modified gene encoding a variant of the wild-type subtilisin from B. clausii | GRN 989 with Amendments (PDF 6.6 MB) |
FDA has no questions (PDF 144 KB) |
| 988 | Lactobacillus fermentum LfQi6 | GRN 988 with Amendments (PDF 9.2 MB) |
FDA has no questions (PDF 137 KB) |
| 987 | 2'-fucosyllactose | GRN 987 with Amendments (PDF 18 MB) |
FDA ceased to evaluate (PDF 235 kB) |
| 986 | Chlorella sorokiniana powder and C. sorokiniana micro powder | GRN 986 (PDF 3.5 MB) |
FDA has no questions (PDF 148 KB) |
| 985 | Bifidobacterium longum subsp. infantis strain ATCC SD 6720 | GRN 985 with Amendments (PDF 11.6 MB) |
FDA has no questions (PDF 338 KB) |
| 984 | Wolffia globosa | GRN 984 with Amendments (PDF 5.4 MB) |
FDA ceased to evaluate (PDF 142 KB) |
| 983 | Purified steviol glycosides from the leaves of Stevia rebaudiana (Bertoni) | GRN 983 (PDF 4.4 MB) |
FDA has no questions (PDF 180 KB) |
| 982 | Polygalacturonase enzyme preparation produced by Aspergillus oryzae expressing a polygalacturonase gene from A. tubingensis Mosseray | GRN 982 (PDF 4.0 MB) |
FDA has no questions (PDF 154 KB) |
| 981 | Sterol esterase enzyme preparation produced by Trichoderma reesei expressing a gene encoding sterol esterase from Melanocarpus albomyces | GRN 981 with Amendments (PDF 4.1 MB) |
FDA has no questions (PDF 255 KB) |
| 980 | Dry whole milk |
GRN 980 |
FDA has no questions (PDF 124 KB) |
| 979 | Pectin esterase enzyme preparation produced by Aspergillus oryzae expressing a pectin esterase gene from A. tubingensis | GRN 979 with Amendments (PDF 2.7 MB) |
FDA has no questions (PDF 143 KB) |
| 978 | Hydrolyzed aqueous olive pulp extract | GRN 978 with Amendments (PDF 4.1 MB) |
FDA has no questions (PDF 256 KB) |
| 977 | D-tagatose produced via novel enzymatic cascade | GRN 977 with Amendments (PDF, 4.0 MB) |
FDA has no questions (PDF 152.32 KB) |
| 976 | Sodium hyaluronate | GRN 976 (PDF 5.0 MB) |
FDA ceased to evaluate (PDF 184 KB) |
| 975 | Maltogenic alpha-amylase enzyme preparation produced by Bacillus licheniformis carrying the gene coding for maltogenic alpha-amylase from Geobacillus stearothermophilus | GRN 975 with Amendments (PDF, 823 KB) |
FDA has no questions (PDF 313 KB) |
| 974 | Maltogenic alpha-amylase enzyme preparation by Bacillus subtilis | GRN 974 (PDF 1.8 MB) |
FDA has no questions (PDF 310 KB) |
| 973 | Maple wood fiber | GRN 973 (PDF 3.1 MB) GRN 973 Amendments (PDF 2.2 MB) |
FDA ceased to evaluate (PDF 169 KB) |
| 972 | Pectin hydrolysate from carrot pomace | GRN 972 (PDF 4.0 MB) GRN 972 Amendments (PDF 2.4 MB) |
FDA has no questions (PDF 124 KB) |
| 971 | Bacillus clausii strain 088AE spore preparation | GRN 971 with Amendments (PDF 9.2 MB) |
FDA has no questions (PDF 150 KB) |
| 970 | Enzyme-modified steviol glycosides | GRN 970 (PDF 4.5 MB) |
FDA has no questions (PDF 225 KB) |
| 969 | Bacillus subtilis "Bss-19" spore preparation | GRN 969 with Amendments (PDF 4.8 MB) |
FDA has no questions (PDF 226 KB) |
| 968 | Rebaudioside B | GRN 968 with Amendments (PDF 3.7 MB) |
FDA has no questions (PDF 227 KB) |
| 967 | Soluble egg-white protein produced by Pichia pastoris strain "DFB-003" | GRN 967 (PDF 23.13 MB) GRN 967 Amendments (PDF 2.1 MB) |
FDA has no questions (PDF 306 KB) |
| 966 | Preparations containing three to eight bacteriophages specific to Campylobacter jejuni | GRN 966 (PDF 13.5 MB) |
FDA has no questions (PDF 313 KB) |
| 965 | Arabinase enzyme preparation produced by Aspergillus tubingensis | GRN 965 (PDF 1.8 MB) GRN 965 Amendments (PDF 24 MB) |
FDA has no questions (PDF 500 KB) |
| 964 | Lysophospholipase enzyme preparation from Aspergillus niger produced by Trichoderma reesei | GRN 964 (PDF 1.9 MB) GRN 964 Amendments (PDF 1.5 MB) |
FDA has no questions (PDF 158 KB) |
| 963 | Fungal oil (≥40% arachidonic acid) from Mortierella alpine | GRN 963 (PDF 17.3 MB) GRN 963 with Amendments (PDF 1.1 MB) |
FDA has no questions (PDF 424 KB) |
| 962 | Rice bran wax | GRN 962 with Amendments (PDF 12 MB) |
FDA ceased to evaluate (PDF 137 KB) |
| 961 | Beta-glucan derived from Agrobacterium sp. CCTCC No. M2010020 | GRN 961 with Amendments (PDF 5.1 MB) |
FDA ceased to evaluate (PDF 245.81 KB) |
| 960 | Hypromellose acetate succinate | GRN 960 (PDF 6.6 MB) |
FDA has no questions (PDF 126 KB) |
| 959 | Iron milk proteinate | GRN 959 (PDF 1.9 MB) |
FDA has no questions (PDF 213 KB) |
| 958 | Fungal oil (≥40% arachidonic acid) from Mortierella alpina strain AF | GRN 958 with Amendments (PDF 1.6 MB) |
FDA ceased to evaluate (PDF 91 KB) |
| 957 | Lactobacillus johnsonii strain ATCC PTA-124205 | GRN 957 (PDF 15 MB) |
FDA has no questions (PDF 171 KB) |
| 956 | Bacillus subtilis PLSSC (ATCC SD 7280) | GRN 956 with Amendments (PDF 1.5 MB) |
FDA has no questions (PDF 130 KB) |
| 955 | Bacillus subtilis strain BS-MB40 PTA-122264 spore preparation | GRN 955 with Amendments (PDF 3 MB) |
FDA has no questions (PDF 244 KB) Supplemental Response Letter (PDF 231 KB) |
| 954 | Fibrillated cellulose | GRN 954 with Amendments (PDF 2.7 MB) |
FDA ceased to evaluate (PDF 111 KB) |
| 953 | Lactobacillus plantarum strain CECT 7527, CECT 7528 and CECT 7529 | GRN 953 Amendment (PDF 4.16 MB) |
FDA has no questions (PDF 279 KB) |
| 952 | Bifidobacterium animalis subsp. lactis strain AD011 | GRN 952 with Amendments (PDF 3.09 MB) |
FDA has no questions (PDF 158.91KB) |
| 951 | 3-fucosyllactose | GRN 951 with Amendments (PDF 5.7 MB) |
FDA has no questions (PDF 272 KB) |
| 950 | Bifidobacterium longa subsq. infantis DSM 33361 | GRN 950 Part 1 (PDF 11.5 MB) GRN 950 Part 2 (PDF 8.9 MB) GRN 950 Part 3 with Amendments (PDF 8.11 MB) |
FDA has no questions (PDF 281 KB) |
| 949 | Bacillus coagulans strain DSM 17654 | GRN 949 (PDF 21.4 MB) |
FDA has no questions (PDF 556 KB) |
| 948 | Enzyme-treated pea protein | GRN 948 (PDF 2.2 MB) |
FDA has no questions (PDF 150 KB) |
| 947 | Cacao pulp, juice and juice concentrate | GRN 947 (PDF 2.93 MB) |
FDA has no questions (PDF 145 KB) |
| 946 | Lactobacillus plantarum strain DSM 33452 | GRN 946 with Amendments (PDF 3.7 MB) |
FDA has no questions (PDF 91 KB) |
| 945 | Fungal protein from Fusarium sp. mycelia | GRN 945 (PDF 2.7 MB) |
FDA has no questions (PDF 141 KB) |
| 944 | Rice protein hydrolysate | GRN 944 with Amendments (PDF 4.6 MB) |
FDA has no questions (PDF 280 KB) |
| 943 | Citrus fiber from the peels of oranges, lemons or limes | GRN 943 (PDF 3.5 MB) |
FDA has no questions (PDF 201 KB) |
| 942 | Whey permeate | GRN 942 (PDF 919 KB) |
FDA ceased to evaluate (PDF 188 KB) |
| 941 | Oat polar lipid extract | GRN 941 (PDF 3.7 MB) |
FDA ceased to evaluate (PDF 124 KB) |
| 940 | Phospholipase A2 enzyme from Sus scrota (wild pig) produced by Yarrowia lipolytica | GRN 940 (PDF 6.1 MB) |
FDA has no questions (PDF 540 KB) |
| 939 | Sunflower lecithin | GRN 939 Part 1 (PDF 10.2 MB) GRN 939 Part 2 with Amendments (PDF 18.8 MB) |
FDA has no questions (PDF 109 KB) |
| 938 | Pichia kluyveri DSM 33235 | GRN 938 (PDF 7.6 MB) |
FDA has no questions (PDF 147 KB) |
| 937 | Staphylococcus carnosus DSM 25010 | GRN 937 (PDF 3.5 MB) |
FDA has no questions (PDF 189 KB) |
| 936 | Leuconostoc carnosum DSM 32756 | GRN 936 (PDF 1.8 MB) |
FDA has no questions (PDF 212 KB) |
| 935 | L-carnitine-L-tartrate | GRN 935 (PDF 3.2 MB) |
FDA ceased to evaluate (PDF 242 KB) |
| 934 | Algal oil (>35% docosahexanoic acid (DHA)) derived from Schizochytrium sp. strain CABIO-A-2 | GRN 934 (PDF 2.0 MB) |
FDA has no questions (PDF 214 KB) |
| 933 | Algal oil (>36% docosahexaenoic acid) from Schizochytrium sp. strain DHF | GRN 933 (PDF 5.1 MB) |
FDA has no questions (PDF 757.41 KB) |
| 932 | 2'-Fucosyllactose | GRN 932 (PDF 10.0 MB) GRN 932 with Amendments (PDF 3.6 MB) |
FDA has no questions (PDF 223 KB) |
| 931 | Creatine monohydrate | GRN 931 (PDF 3.1 MB) |
FDA has no questions (PDF 437 KB) |
| 930 | Silk protein derived from bombyx cocoons | GRN 930 Part 1 (PDF 18 MB) GRN 930 Part 2 (PDF 4.5 MB) GRN 930 Part 3 (PDF 6.8 MB) |
FDA ceased to evaluate (PDF 125 KB) |
| 929 | 2'-fucosyllactose | GRN 929 (PDF 3.6 MB) GRN 929 with Amendments (PDF 7 MB) |
FDA has no questions (PDF 267 KB) |
| 928 | Dried Saccharomyces cerevisiae yeast fermentate | GRN 928 (PDF 12 MB) GRN 928 with Amendments (PDF 3.7 MB) |
FDA has no questions (PDF 248 KB) |
| 927 | Polyvinyl alcohol | GRN 927 (PDF 4.0 MB) GRN 927 with Amendments (PDF 5.2 MB) |
FDA has no questions (PDF 205.85 KB) |
| 926 | Soluble rice flour | GRN 926 (PDF 6.32 MB) |
FDA has no questions (PDF 434 KB) |
| 925 | 3'-Fucosyllactose | GRN 925 (PDF 4.13 MB) |
FDA has no questions (PDF 190 KB) |
| 924 | 2'-Fucosyllactose | GRN 924 with Amendments (PDF 2.4 MB) |
FDA ceased to evaluate (PDF 242 KB) |
| 923 | Lacto-N-neotetraose | GRN 923 with Amendments (PDF 2.3 MB) |
FDA has no questions (PDF 187 KB) |
| 922 | 6'-sialyllactose sodium salt | GRN 922 with Amendments (PDF 1.69 MB) |
FDA has no questions (PDF 243 KB) |
| 921 | 3'-sialyllactose sodium salt | GRN 921 (PDF 2.2 MB) |
FDA has no questions (PDF 771 KB) |
| 920 | Thaumatin II | GRN 920 (PDF 5.8 MB) |
FDA has no questions (PDF 170 KB) |
| 919 | Lacto-N-neotetraose | GRN 919 (PDF 1.4 MB) |
FDA has no questions (PDF 353 KB) |
| 918 | Partially defatted almond protein flour | GRN 918 (PDF 1.4 MB) GRN 918 with Amendments (PDF 10.0 MB) |
FDA has no questions (PDF 206 KB) |
| 917 | Preparation containing three bacterial phages specific to Salmonella | GRN 917 (PDF 3.1 MB) |
FDA has no questions (PDF 539.77 KB) |
| 916 | Dihydroquercetin | GRN 916 with Amendments (PDF 11 MB) |
FDA has no questions (PDF 245 KB) |
| 915 | Calcium L-methylfolate | GRN 915 (PDF 3.8 MB) |
FDA has no questions (PDF 217 KB) |
| 914 | Alpha-linolenic acid diacylglycerol | GRN 914 with Amendments (PDF 3.9 MB) |
FDA has no questions (PDF 175 KB) |
| 913 | Algal oil (minimum 35% DHA) | GRN 913 (PDF 4.1 MB) |
FDA has no questions (PDF 906 KB) |
| 912 | Trehalose | GRN 912 (PDF 2.5 MB) |
FDA ceased to evaluate (PDF 140 KB) |
| 911 | Rebaudioside I | GRN 911 (PDF 14.6 MB) |
FDA has no questions (PDF 208 KB) |
| 910 | Thaumatin II produced in Nicotiana benthamiana | GRN 910 (PDF 2.8 MB) |
FDA has no questions (PDF 541 KB) |
| 909 | Whey protein containing 41% alpha-lactalbumin | GRN 909 Amendment (PDF 1.1 MB) |
FDA ceased to evaluate (PDF 123 KB) |
| 908 | Lipase from Penicillium camemberti | GRN 908 Amendment (PDF 2.1 MB) |
FDA has no questions (PDF 184 KB) |
| 907 | Wheat seed oil | GRN 907 (PDF 10.45 MB) |
FDA has no questions (PDF 593 KB) |
| 906 | Wheat polar lipids | GRN 906 (PDF 3.8 MB) |
FDA has no questions (PDF 518 KB) |
| 905 | Bacilllus subtilis SG188 | GRN 905 (PDF 4.4 MB) |
FDA has no questions (PDF 659 KB) |
| 904 | Fungal protein from fermented Fusarium sp. mycelia |
GRN 904 Amendment |
FDA has no questions (PDF 956 KB) |
| 903 | Quillaia extract type 2 | GRN 903 (PDF 2.4 MB) GRN 903 Amendment (PDF 8.4 MB) |
FDA has no questions (PDF 194 KB) |
| 902 | Neohesperidin dihydrochalcon | GRN 902 (PDF 9 MB) |
FDA has no questions (PDF 408 KB) |
| 901 | Glucosyl hesperidin |
GRN 901 |
FDA has no questions (PDF 670 KB) |
| 900 | Corn oil | GRN 900 (PDF 5.2 MB) |
FDA has no questions (PDF 539 KB) |
| 899 | Citric acid esters of mono- and diglycerides | GRN 899 (PDF 2.1 MB) |
FDA has no questions (PDF 624 KB) |
| 898 | Dried milk fat |
GRN 898 |
FDA has no questions (PDF 650 KB) |
| 897 | 2'-O-fucosyllactose | GRN 897 (PDF 1.8 MB) |
FDA has no questions (PDF 715 KB) |
| 896 | Alpha-galacto-oligosaccharides | GRN 896 with Amendments (PDF 5.9 MB) |
FDA has no questions (PDF 202 KB) |
| 895 | Lacto-N-neotetraose | GRN 895 (PDF 3.1 MB) |
FDA has no questions (PDF 858 KB) |
| 894 | White mulberry leaf extract | GRN 894 (PDF 6 MB) |
FDA ceased to evaluate (PDF 200 KB) |
| 893 | Allulose | GRN 893 with Amendments (PDF 10.6 MB) |
FDA ceased to evaluate (PDF 58 KB) |
| 892 | Refined shea butter | GRN 892 (PDF 11.8 MB) |
FDA ceased to evaluate (PDF 162 KB) |
| 891 | Cellulase produced by Trichoderma reesei | GRN 891 with Amendments (PDF 2.1 MB) |
FDA has no questions (PDF 512 KB) |
| 890 | Corn oil derived from distillers grains |
GRN 890 Part 1 |
FDA ceased to evaluate (PDF 189 KB) |
| 889 | Wheat germ extract | GRN 889 (PDF 8.4 MB) |
FDA ceased to evaluate (PDF 236 KB) |
| 888 | Preparation containing three bacterial phages specific to Salmonella | GRN 888 (PDF 8.3 MB) |
FDA ceased to evaluate (PDF 36 KB) |
| 887 | Menaquinone-7 | GRN 887 (PDF 9 MB) |
FDA has no questions (PDF 472 KB) |
| 886 | Mixture of monoacylglycerides derived from grape seed | GRN 886 (PDF 5 MB) |
FDA has no questions (PDF 514 KB) |
| 885 | Vinyl Acetate-Vinyl Laurate Copolymers (VAVLP) as components of Chewing Gum Base | GRN 885 (PDF 2.2 MB) |
FDA has no questions (PDF 451 KB) |
| 884 | Rice bran extract | GRN 884 (PDF 11.8 MB) |
FDA has no questions (PDF 518 KB) |
| 883 | Ilex guayusa leaf hydroethanolic extract | GRN 883 (PDF 18.7 MB) |
FDA has no questions (PDF 514 KB) |
| 882 | Rebaudioside M | GRN 882 (PDF 1.4 MB) |
FDA has no questions (PDF 479 KB) |
| 881 | 6'-sialyllactose sodium salt | GRN 881 (PDF 4.5 MB) |
FDA has no questions (PDF 561 KB) |
| 880 | 3'-sialyllactose sodium salt | GRN 880 (PDF 4.6 MB) |
FDA has no questions (PDF 557 KB) |
| 879 | Fava bean protein | GRN 879 (PDF 6 MB) |
FDA has no questions (PDF 502 KB) |
| 878 | Glucosylated steviol glycosides | GRN 878 (PDF 16 MB) |
FDA has no questions Supplemental Response Letter |
| 877 | Bifidobacterium longum BB536 | GRN 877 (PDF 5.2 MB) |
FDA has no questions (PDF 74 KB) |
| 876 | Hydroxytyrosol | GRN 876 with Amendments (PDF 4.4 MB) |
FDA has no questions (PDF 88 KB) |
| 875 | Bifidobacterium animalis subsp. lactis AD011 | GRN 875 (PDF 3 MB) |
FDA ceased to evaluate (PDF 258 KB) |
| 874 | Corn protein | GRN 874 (PDF 3 MB) |
FDA ceased to evaluate (PDF 44 KB) |
| 873 | Cranberry extract | GRN 873 (PDF 4 MB) |
FDA has no questions (PDF 567 KB) |
| 872 | Bifidobacterium animalis subsp. lactic UABla-12 | GRN 872 (PDF 3.4 MB) |
FDA has no questions (PDF 61 KB) |
| 871 | Lactobacillus acidophilus DDS-1 | GRN 871 (PDF 4.0 MB) |
FDA has no questions (PDF 49 KB) |
| 870 | Ilex guayusa leaf hydroethanolic extract | GRN 870 (PDF 20 MB) |
FDA has no questions (PDF 550 KB) |
| 869 | Ilex guayusa leaf extract | GRN 869 (PDF 20 MB) |
FDA has no questions (PDF 550 KB) |
| 868 | Coffee fruit extract | GRN 868 (PDF 3 MB) |
FDA has no questions (PDF 556 KB) |
| 867 | Rebaudioside M | GRN 867 (PDF 1.8 MB) |
FDA ceased to evaluate (PDF 35 KB) |
| 866 | Lipase from Penicillium camemberti | GRN 866 (PDF 653 KB) |
FDA ceased to evaluate (PDF 257 KB) |
| 865 | Lactobacillus acidophilus NCFM | GRN 865 (PDF 9.33 MB) |
FDA has no questions (PDF 761 KB) |
| 864 | Bacillus coagulans SNZ 1969 spore preparation | GRN 864 (PDF 8.3 MB) |
FDA has no questions (PDF 560 KB) |
| 863 | B-lactoglobulin produced by Trichoderma reesei | GRN 863 (PDF 5.2 MB) |
FDA has no questions (PDF 637 KB) |
| 862 | Algal oil (40% docosahexaenoic acid) from Schizochytrium sp. strain ONC-T18 | GRN 862 (PDF 18.26 MB) |
FDA has no questions (PDF 748 KB) |
| 861 | Pullulanase from Bacillus deramificansproduced in Bacillus subtilis | GRN 861 (PDF 1.3 MB) |
FDA has no questions (PDF 605 KB) |
| 860 | Algal oil (36% docosahexaenoic acid) from Schizochytrium sp. strain DHF | GRN 860 (PDF 8.6 MB) |
FDA ceased to evaluate (PDF 35 KB) |
| 859 | 2'-fucosyllactose | GRN 859 (PDF 13 MB) |
FDA ceased to evaluate (PDF 248 KB) |
| 858 | Glucosylated steviol glycosides | GRN 858 Part 1 (PDF 1.5 MB) GRN 858 Part 2 (PDF 9 MB) GRN 858 Part 3 (PDF 6 MB) |
FDA has no questions (PDF 86 KB) |
| 857 | Phospholipase A1 produced by Aspergillus niger | GRN 857 (PDF 1.8 MB) |
FDA has no questions (PDF 465 KB) |
| 856 | Bifidobacterium animalis subsp. lactis strain BB-12 | GRN 856 (PDF 10.94 MB) |
FDA has no questions (PDF 63 KB) |
| 855 | Bifidobacterium animalis ssp. lactis strain R0421 | GRN 855 (PDF 5.0 MB) |
FDA has no questions (PDF 634 KB) |
| 854 | Inulin from Agave tequilana | GRN 854 (PDF 28.5 MB) |
FDA has no questions (PDF 2 MB) |
| 853 | Lysozyme produced by Trichoderma reesei | GRN 853 (PDF 1 MB) |
FDA has no questions (PDF 552 KB) |
| 852 | 2-fucosyllactose | GRN 852 (PDF 9.4 MB) |
FDA has no questions (PDF 108 KB) |
| 851 | Pea protein | GRN 851 (PDF 1.6 MB) |
FDA has no questions (PDF 601 KB) |
| 850 | Shea olein | GRN 850 (PDF 13.4 MB) |
FDA has no questions (PDF 610 KB) |
| 849 | Inulin from artichoke | GRN 849 (PDF 8.56 MB) |
FDA has no questions (PDF 129 KB) |
| 848 | Pea and rice protein fermented by Shitake mycelia | GRN 848 (PDF 7.6 MB) |
FDA has no questions (PDF 487 KB) |
| 846 | Rebaudioside M | FDA has no questions (PDF 102 KB) |
|
| 847 | Lactobacillus plantarum ECGC 13110402 | GRN 847 (PDF 4.7 MB) |
FDA has no questions (PDF 63 KB) |
| 846 | Rebaudioside M | GRN 846 (PDF 4 MB) |
|
| 845 | Lactobacillus rhamnosus LGG | GRN 845 (PDF 7.6 MB) |
FDA has no questions (PDF 121 KB) |
| 844 | Algal oil (55% docosahexaenoic acid) from Schizochytrium sp. strain FCC-3204 | GRN 844 (PDF 3.4 MB) |
FDA has no questions (PDF 105 KB) |
| 843 | Algal oil (35% docosahexaenoic acid) from Schizochytrium sp. strain FCC-1324 | GRN 843 (PDF 4.9 MB) |
FDA has no questions (PDF 85 KB) |
| 842 | Maltogenic alpha-amylase | GRN 842 (PDF 1.03 MB) |
FDA has no questions (PDF 715 KB) |
| 841 | Saccharomyces cerevisiae expressing L-lactate dehydrogenase from Rhizopus oryzae | GRN 841 (PDF 2.7 MB) |
FDA has no questions (PDF 604 KB) |
| 840 | Lactobacillus paracasei strain F19 | GRN 840 (PDF 3 MB) |
FDA has no questions (PDF 76 KB) |
| 839 | Purified steviol glycosides | GRN 839 (PDF 3.9 MB) |
FDA has no questions (PDF 77 KB) |
| 838 | Purified steviol glycosides | GRN 838 (PDF 4.5 MB) |
FDA has no questions (PDF 83 KB) |
| 837 | Hydroxytyrosol | GRN 837 (PDF 2.7 MB) |
FDA ceased to evaluate (PDF 54 KB) |
| 836 | Algal oil (50-60% docosahexaenoic acid) from Schizochytrium sp. HS01 | GRN 836 (PDF 2.3 MB) |
FDA has no questions (PDF 74 KB) |
| 835 | Ilex guayusa leaf extract | GRN 835 (PDF 6.8 MB) |
FDA ceased to evaluate (PDF 35.24 KB) |
| 834 | Preparation containing bacterial phages specific to shiga-toxin Escherichia coli | GRN 834 (PDF 11.69 MB) |
FDA has no questions (PDF 91 KB) Supplemental Response Letter (PDF 229 kB) |
| 833 | Lacto-N-tetraose | GRN 833 with Amendments (PDF 11MB) |
FDA has no questions (PDF 701 KB) |
| 832 | Acid prolyl endopeptidase produced by Aspergillus niger | GRN 832 (PDF 2.6 MB) |
FDA has no questions (PDF 284.21 KB) |
| 831 | Bacillus subtilis DE111 | GRN 831 (PDF 6.4 MB) |
FDA has no questions (PDF 73 KB) |
| 830 | Chicory flour | GRN 830 (PDF 1.51 MB) |
FDA ceased to evaluate (PDF 53.77 KB) |
| 829 | Dried biomass of Aspergillus oryzae fermented with minerals | GRN 829 (PDF 1.3 MB) |
FDA has no questions (PDF 110 KB) Additional correspondence (PDF 104 KB) |
| 828 | D-psicose | GRN 828 (PDF 1.4 MB) |
FDA has no questions (PDF 550 KB) |
| 827 | Preparation containing three bacterial phages specific to Escherichia coli serotypes | GRN 827 (PDF 20 MB) |
FDA has no questions (PDF 75.92 KB) Additional correspondence (PDF 447 KB) |
| 826 | Dihydroquercetin | GRN 826 (PDF 15.4 MB) |
FDA ceased to evaluate (PDF 35 KB) |
| 825 | Beta-galactosidase from Kluyveromyces lactis | GRN 825 (PDF 5.0 MB) |
FDA has no questions (PDF 64 KB) |
| 824 | Bacteriocin preparations specific to Salmonella | GRN 824 (PDF 6.7 MB) |
FDA has no questions |
| 823 | Rebaudioside E | GRN 823 (PDF 6.2 MB) |
FDA has no questions (PDF 757 KB) |
| 822 | Curcumin | GRN 822 (PDF 4.8 MB) |
FDA has no questions (PDF 861 KB) |
| 821 | Glucosylated steviol glycosides | GRN 821 (PDF 1.6 MB) |
FDA has no questions (PDF 743 KB) |
| 820 | Lactobacillus fermentum CECT5716 | GRN 820 (PDF 3.62 MB) |
GRN 820 (PDF 35.2 KB) |
| 819 | Fatty acid ethyl esters from Alaskan Pollock | GRN 819 (PDF 6 MB) |
FDA has no questions (PDF 63 KB) |
| 818 | Isomalto-oligosaccharides | GRN 818 (PDF 3.83 MB) |
FDA has no questions (PDF 126.11 KB) |
| 817 | Serine endopetidase from Melbranchea cinnamomea produced in Trichaderma reesei | GRN 817 (PDF 3.5 MB) |
FDA has no questions (PDF 67.82 KB) |
| 816 | Xylooligosaccharides from sugarcane | GRN 816 (PDF 8.3 MB) |
GRN 816 (PDF 68.2 KB) |
| 815 | 2' -fucosyllactose and difucosyllactose | GRN 815 (PDF 3.3 MB) |
FDA has no questions Correction Letter Correction Letter |
| 814 | Bifidobacterium bifidum BGN4 | GRN 814 (PDF 2.5 MB) |
FDA has no questions (PDF 78 KB) |
| 813 | Bifidobacterium longum BORI | GRN 813 (PDF 1.7 MB) |
FDA has no questions (PDF 82 KB) |
| 812 | Rebaudioside M | GRN 812 (PDF 8 MB) |
FDA has no questions (PDF 659 KB) |
| 811 | Phospholipase A1 produced by Aspergillus oryzae | GRN 811 (PDF 1.5 MB) |
FDA has no questions (PDF 64 KB) |
| 810 | Lactobacillus paracasei subsp. paracasei strain F-19e | GRN 810 (PDF 1.7 MB |
GRN 810 (PDF 178 KB) |
| 809 | Fractionated whey protein concentrate containing 41% alphalactalbumin | GRN 809 (PDF 6.2 MB) |
FDA has no questions (PDF 315.2 KB) |
| 808 | Lipase from Aspergillus tubingensis produced in Trichoderma reesei | GRN 808 (PDF 2.4 MB) |
FDA has no questions (PDF 79.73 KB) |
| 807 | Streptococcus salivarius M18 | GRN 807 (PDF 2.4 MB) |
FDA has no questions (PDF 66 KB) |
| 806 | Dolomite | GRN 806 (PDF 747.31 KB) |
GRN 806 (PDF 275 KB) |
| 805 | Apple peel powder | GRN 805 (PDF 5.0 MB) |
FDA has no questions (PDF 522 kB) |
| 804 | Pea protein | GRN 804 (PDF 5 MB) |
FDA has no questions (PDF 94 KB) |
| 803 | Pea protein | GRN 803 (PDF 1.1 MB) |
FDA has no questions (PDF 91 KB) |
| 802 | Endolysin | GRN 802 (PDF 5.5 MB) |
GRN 802 (PDF 294 KB) |
| 801 | Chymosin enzyme from Camelus dromendarius produce in Aspergillus niger | GRN 801 (PDF 15 MB) |
FDA has no questions (PDF 71 KB) |
| 800 | Gamma-oryzanol | GRN 800 Part 1 (PDF 8 MB) GRN 800 Part 2 (PDF 17 MB) |
FDA has no questions (PDF 628 KB) |
| 799 | Rebaudioside M | GRN 799 (PDF 1.2 MB) |
FDA has no questions (PDF 112 KB) |
| 798 | Saccharomyces cerevisiae strain yBBS002 | GRN 798 (PDF 5.6 MB) |
FDA has no questions (PDF 73.19 KB) |
| 797 | Fructooligosaccharides | GRN 797 (PDF 16 MB |
FDA has no questions (PDF 450 KB) |
| 796 | Orange extract (85% hesperidin) | GRN 796 (PDF 11 MB) |
FDA has no questions (PDF 459 KB) |
| 795 | Purified steviol glycosides | GRN 795 (PDF 10 MB) |
FDA has no questions (PDF 106 KB) |
| 794 | Shiitake, pea, and rice protein fermented with Lentinula edodes | GRN 794 (PDF 11.9 MB) |
FDA ceased to evaluate this notice (PDF 57 KB) |
| 793 | Cultured corn starch fermented by Corynebacterium stationis | GRN 793 (PDF 5.1 MB) |
GRN 793 (PDF 171 KB) |
| 792 | Cultured corn starch fermented by Corynebacterium glutamicum | GRN 792 (PDF 7.6 MB) |
GRN 792 (PDF 160 KB) |
| 791 | Urolithin A | GRN 791 (PDF 2.3 MB) |
FDA has no questions (PDF 61 KB) |
| 790 | Steviol glycosides | GRN 790 (PDF 4 MB) |
FDA has no questions (PDF 448 KB) |
| 789 | Erythritol | GRN 789 Part 1 (PDF 13.8 MB) GRN 789 Part 2 (PDF 13.1 MB) |
FDA has no questions (PDF 80 KB) |
| 788 | Pea protein | GRN 788 (PDF 7.3 MB) |
FDA has no questions (PDF 246 KB) |
| 787 | Quinoa sprout powder | GRN 787 (PDF 12.9 MB) |
FDA has no questions (PDF 94 KB) |
| 786 | Calcium propionate | GRN 786 (PDF 2.8 MB) |
FDA has no questions (PDF 70 KB) |
| 785 | Calcium chloride | GRN 785 (PDF 1.3 MB) |
FDA has no questions (PDF 74 KB) |
| 784 | Siraitia grosvenorii Swingle | GRN 784 (PDF 3 MB) |
FDA has no questions (PDF 664 KB) |
| 783 | Triacylglycerol lipase from Rhizopus oryzae produced in Aspergillus niger | GRN 783 Part 1 (PDF 2.7 MB) GRN 783 Part 2 (PDF 17 MB) GRN 783 Part 3 (PDF 5.9 MB) GRN 783 Part 4 (PDF 6.4 MB) |
FDA has no questions (PDF 75 KB) |
| 782 | L-arabinose | GRN 782 (PDF 9.02 MB) |
FDA has no questions (PDF 47 KB) |
| 781 | Alpha-tocopherol (fruit and vegetable derived) | GRN 781 (PDF 3 MB) |
FDA has no questions (PDF 1 MB) |
| 780 | Rebaudioside M | GRN 780 (PDF 1 MB) |
FDA has no questions (PDF 115 KB) |
| 779 | Isomalto-oligosaccharide mixture | GRN 779 (PDF 12 MB) |
FDA has no questions (PDF 89 KB) |
| 778 | Hemp seed oil | GRN 778 (PDF 19 MB) GRN 778 Amendment (PDF 352 kB) |
FDA has no questions Supplemental Response Letter |
| 777 | Algal oil (55% docosahexaenoic acid) from Schizochytrium sp. FCC-3204 | GRN 777 (PDF 13.4 MB) |
FDA has no questions (PDF 230 KB) |
| 776 | Algal oil (35% docosahexaenoic acid) from Schizochytrium sp. FCC-1324 | GRN 776 (PDF 1.58 MB) |
FDA has no questions (PDF 570 KB) |
| 775 | colicin proteins produced in Nicotiana benthamiana (colicin preparations) | GRN 775 (PDF 3.34 MB) |
FDA has no questions (PDF 77 KB) |
| 774 | Glutaminase from Bacillus licheniformis produced in Bacillus licheniformis | GRN 774 (PDF 1.28 MB) |
FDA has no questions (PDF 73 KB) |
| 773 | Dried biomass of Chlamydomonas reinhardtii | GRN 773 (PDF 4.99 MB) |
FDA has no questions (PDF 149 KB) |
| 772 | Palmitoylated green tea catechins | GRN 772 (PDF 1.68 MB) |
FDA has no questions (PDF 63 KB) |
| 771 | Hemp seed protein | GRN 771 Part 1 (PDF 4.4 MB) GRN 771 Part 2 Amendment (PDF 14.9 MB) GRN 771 Part 3 Amendment (PDF 352 KB) |
FDA has no questions Supplemental Response Letter |
| 770 | Potassium polyaspartate | GRN 770 (PDF 1.28 MB) |
FDA has no questions (PDF 786 KB) |
| 769 | Vitamin C (fruit and vegetable derived) | GRN 769 (PDF 770 KB) |
FDA has no questions (PDF 72 KB) |
| 768 | Stevia leaf extract | GRN 768 (PDF 2 MB) |
FDA has no questions (PDF 100 KB) |
| 767 | Polyvinyl alcohol | GRN 767 (PDF 502.88 KB) |
FDA has no questions (PDF 57 KB) |
| 766 | 3’-sialyllactose sodium salt | GRN 766 (PDF 919 KB) |
FDA has no questions |
| 765 | Hulled hemp seed | GRN 765 (PDF 19 MB) GRN 765 Amendment (PDF 352 kB) |
FDA has no questions Supplemental Response Letter |
| 764 | Rebaudioside D | GRN 764 (PDF 8.46 MB) |
FDA has no questions (PDF 111 KB) |
| 763 | Alpha-lactalbumin | GRN 763 with Amendments (PDF 2.5 MB) |
FDA has no questions (PDF 106 KB) |
| 762 | Carnobacterium divergens M35 preparation | GRN 762 (PDF 5.4 MB) |
FDA has no questions (PDF 32 KB) |
| 761 | Esterified propoxylated glycerol | GRN 761 (PDF 3.2 MB) |
FDA has no questions (PDF 106 KB) |
| 760 | Lactobacillus curvatus DSM 18775 | GRN 760 (PDF 3.7 MB) |
FDA has no questions (PDF 77 KB) |
| 759 | Steviol glycosides consisting primarily of rebaudioside M produced in Yarrowia lipolytica | GRN 759 (PDF 3.7 MB) |
FDA has no questions (PDF 106 KB) |
| 758 | Lactobacillus helveticus R0052, Bifidobacterium longum ssp. infantis R0033, and Bifidobacterium bifidum R0071 | GRN 758 (PDF 5 MB) GRN 758 Amendment (PDF 630 kB) |
FDA has no questions (PDF 103 KB) |
| 757 | Escherichia coli O157 | GRN 757 (PDF 2 MB) |
FDA has no questions (PDF 59 KB) |
| 756 | Endo-1,4-beta-glucanase from Trichoderma reesei | GRN 756 (PDF 3.5 MB) |
FDA has no questions (PDF 92 KB) |
| 755 | D-psicose | GRN 755 (PDF 545 kB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 57 KB) |
| 754 | Algal oil (87% oleic acid) derived from Prototheca moriformis strain S6697 | GRN 754 (PDF 15 MB) |
FDA has no questions (PDF 87 KB) |
| 753 | Sodium Thiocyanate | GRN 753 (PDF 6.9 MB) |
FDA has no questions (PDF 56 KB) |
| 752 | Preparation containing the bacterial monophages, BP-63 and LVR16-A, specific to Salmonella | GRN 752 (PDF 2.3 MB) |
FDA has no questions (PDF 57 KB) Supplemental Response Letter (PDF 130 KB) |
| 751 | Maltogenic alpha-amylase from Bacillus stearothermophilus produced in Bacillus subtilis | GRN 751 (PDF 1.1 MB) |
FDA has no questions (PDF 228 KB) |
| 750 | Beta-glucosidase | GRN 750 Part 1 (PDF 7.7 MB) GRN 750 Part 2 (PDF 16.4 MB) GRN 750 Part 3 (PDF 14 MB) GRN 750 Part 4 (PDF 20 MB) |
FDA has no questions (PDF 767 KB) |
| 749 | 2’-O-fucosyllactose | GRN 749 Part 1 (PDF 10.6 MB) GRN 749 Part 2 (PDF 12.2 MB) |
FDA has no questions (PDF 96 KB) |
| 748 | Tomato powder | GRN 748 (PDF 3.4 MB) |
FDA ceased to evaluate (PDF 45 KB) |
| 747 | Calcium lactate | GRN 747 (PDF 2.2 MB) |
FDA has no questions (PDF 76 KB) |
| 746 | Maltogenic amylase from Geobacillus stearothermophilus produced in Bacillus subtilis | GRN 746 (PDF 7.1 MB) |
FDA has no questions (PDF 104 KB) |
| 745 | Steviol glycosides consisting primarily of rebaudioside M | GRN 745 (PDF 1 MB) |
FDA has no questions (PDF 139 KB) |
| 744 | Steviol glycosides consisting primarily of rebaudioside M | GRN 744 (PDF 1.9 MB) |
FDA has no questions (PDF 131 KB) |
| 743 | β-galactosidase from Papiliotrema terrestris | GRN 743 (PDF 8.7 MB) |
FDA has no questions (PDF 69 KB) |
| 742 | Duckweed (subfamily Lemnoideae) powder | GRN 742 Part 1 (PDF 9 MB) GRN 742 Part 2 (PDF 8.7 MB) GRN 742 Part 3 (PDF 11.5 MB) |
FDA has no questions (PDF 64 KB) |
| 741 | Dimethyl ether | GRN 741 (PDF 403 KB) |
FDA has no questions (PDF 72 KB) |
| 740 | Glycolipids from Dacryopinax spathularia | GRN 740 (PDF 3.7 MB) |
FDA has no questions (PDF 94 KB) Supplemental Response Letter (PDF 273 kB) |
| 739 | Mannanase enzyme from Talaromyces leycettanus produced in Aspergillus niger | GRN 739 (PDF 622 KB) |
FDA has no questions (PDF 113 KB) |
| 738 | Thaumatin | GRN 738 (PDF 1.8 MB) |
FDA has no questions (PDF 77 KB) |
| 737 | Soy leghemoglobin | GRN 737 Part 1 (PDF 10.1 MB) GRN 737 Part 2 (PDF 9.2 MB) GRN 737 Part 3 (PDF 10.4 MB) |
FDA has no questions (PDF 80 KB) |
| 736 | Lactobacillus casei subsp. paracasei Lpc-37 | GRN 736 (PDF 17.6 MB) |
FDA has no questions (PDF 73 KB) |
| 735 | 2’-Fucosyllactose | GRN 735 Part 1 (PDF 15.5 MB) GRN 735 Part 2 (PDF 16.3 MB) GRN 735 Part 3 (PDF 10.3 MB), GRN 735 Part 4 (PDF 14.8 MB) GRN 735 Part 5 (PDF 11.8 MB) |
FDA has no questions (PDF 103 KB) Supplemental Response Letter (PDF 176 KB) |
| 734 | Ergothionine | GRN 734 (PDF 18.5 MB) |
FDA has no questions (PDF 70 KB) |
| 733 | Purified steviol glycosides | GRN 733 Part 1 (PDF 9.8 MB) GRN 733 Part 2 (PDF 15 MB) |
FDA has no questions (PDF 69 KB) |
| 732 | Docosahexaenoic acid oil produced in Schizochytrium sp. | GRN 732 (PDF 5.3 MB) |
FDA has no questions (PDF 68 KB) |
| 731 | Docosahexaenoic acid oil produced in Schizochytrium sp. | GRN 731 (PDF 454 KB) |
FDA has no questions (PDF 72 KB) |
| 730 | Arachidonic Acid Oil Produced in Mortierella Alpina | GRN 730 (PDF 6.8 MB) |
FDA has no questions (PDF 77 KB) |
| 729 | Galacto-oligosaccharides | GRN 729 (PDF 15 MB) |
FDA has no questions (PDF 112 KB) |
| 728 | Phospholipase C from Pseudomonas sp. 62186 produced in Bacillus licheniformis | GRN 728 (PDF 730 KB) |
FDA has no questions (PDF 47 KB) |
| 727 | Trehalase from Trichoderma reesei produced in Trichoderma reesei | GRN 727 (PDF 4.9 MB) |
FDA has no questions (PDF 61 KB) |
| 726 | Polyphenol extract from olive | GRN 726 (PDF 7.5 MB) |
FDA has no questions (PDF 66 KB) |
| 725 | Inactivated Bacillus coagulans GBI-30, 6086 | GRN 725 (PDF 5.2 MB) |
FDA has no questions (PDF 52 KB) |
| 724 | Preparation containing six bacterial phages specific to shiga-toxin producing Escherichia coli | GRN 724 (PDF 4.2 MB) |
FDA has no questions (PDF 75 KB) |
| 723 | Benzalkonium chloride | GRN 723 (PDF 18.6 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 41 KB) |
| 722 | Lactobacillus plantarum Lp-115 | GRN 722 (PDF 10.3 MB) |
FDA has no questions (PDF 67 KB) |
| 721 | Galacto-oligosaccharides | GRN 721 (PDF 10 MB) |
FDA has no questions (PDF 69 KB) |
| 720 | Rice bran wax | GRN 720 (PDF 23.4 MB) |
FDA has no questions (PDF 73 KB) |
| 719 | Orange pomace | GRN 719 (PDF 2.1 MB) |
FDA has no questions (PDF 66 KB) |
| 718 | Calcium acid pyrophosphate | GRN 718 Amendment (PDF 1 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 32 KB) |
| 717 | Short-chain fructo-oligosaccharides | GRN 717 (PDF 4.1 MB) |
FDA has no questions (PDF 82 KB) Supplemental Response Letter (PDF 225 KB) |
| 716 | Bovine milk osteopontin | GRN 716 Part 1 with Amendments (PDF 19.9 MB) GRN 716 Part 2 (PDF 483 KB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 32 KB) |
| 715 | Rebaudioside D | GRN 715 (PDF 2.9 MB) |
FDA has no questions (PDF 69 KB) |
| 714 | Subtilisin from Bacillus amyloliquefaciens produced in Bacillus subtilis | GRN 714 (PDF 10.8 MB) |
FDA has no questions (PDF 53 KB) |
| 713 | Hydrolyzed pork cartilage | GRN 713 (PDF 636 KB) |
FDA has no questions (PDF 65 KB) |
| 712 | Calcium acetate | GRN 712 (PDF 11.9 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 44 KB) |
| 711 | Glucan | GRN 711 (PDF 1.8 MB) |
FDA has no questions (PDF 49 KB) |
| 710 | Basic methacrylate copolymer | GRN 710 (PDF 414 KB) GRN 710 Amendments (PDF 1.0 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 50 KB) |
| 709 | Pyrroloquinoline quinone disodium salt | GRN 709 (PDF 1.55 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 79 KB) |
| 708 | Triacylglycerol lipase from Rhizopus oryzae produced in Aspergillus niger | At the notifier's request, FDA ceased to evaluate this notice (PDF 52 KB) |
|
| 707 | Glucose oxidase from Penicillium produced in Trichoderma reesei | GRN 707 (PDF 22 MB) |
FDA has no questions (PDF 51 KB) |
| 706 | Siraitia grosvenorii Swingle (Luo Han Guo) fruit extract | GRN 706 (PDF 16.6 MB) |
FDA has no questions (PDF 93 KB) |
| 705 | Distarch phosphate | GRN 705 (PDF 21.1 MB) |
FDA has no questions (PDF 63 KB) |
| 704 | Corn oil (by-product of ethanol production) | GRN 704 (PDF 8.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 67 KB) |
| 703 | Alpha-glucosidase from Aspergillus niger produced by Trichoderma reesi | GRN 703 (PDF 10 MB) |
FDA has no questions (PDF 128 KB) |
| 702 | Purified steviol glycosides | GRN 702 (PDF 11.5 MB) |
FDA has no questions (PDF 65 KB) |
| 701 | Pyrroloquinoline quinone disodium salt | GRN 701 (PDF 3.7 MB) |
FDA has no questions (PDF 68 KB) |
| 700 | Paracoccus carotinifaciens extract containing carotenoids | GRN 700 (PDF 17 MB) |
FDA has no questions (PDF 99 KB) |
| 699 | Trehalase from Myceliophthora sepedonium produced by Aspergillus niger | GRN 699 (PDF 4.2 MB) |
FDA has no questions (PDF 67 KB) |
| 698 | Paramylon isolate from Euglena gracilis | GRN 698 (PDF 4.7 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 105 KB) |
| 697 | Dried biomass of Euglena gracilis | GRN 697 (PDF 4.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 105 KB) |
| 696 | Dolomite | GRN 696 (PDF 897 kB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 53 KB) |
| 695 | Dimethyl ether | GRN 695 (PDF 1.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 46 KB) |
| 694 | Pyrroloquinoline quinone disodium salt (PQQ) | GRN 694 (PDF 6.7 MB) |
FDA has no questions (PDF 72 KB) |
| 693 | D-psicose | GRN 693 (PDF 1.6 MB) |
FDA has no questions (PDF 97 KB) |
| 692 | Quinoa sprout extract | GRN 692 (PDF 1.8 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 33 KB) |
| 691 | Bacillus coagulans SANK 70258 spore preparation | GRN 691 (PDF 14.3 MB) |
FDA has no questions (PDF 54 KB) |
| 690 | Fruit and vegetable vitamin extract | GRN 690 with Amendments (PDF 2.6 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 117 KB) |
| 689 | Phospholipase C from Bacillus thuringiensis produced in Bacillus licheniformis | GRN 689 (PDF 870 KB) |
FDA has no questions (PDF 54 KB) |
| 688 | Sodium thiocyanate | GRN 688 (PDF 2.2 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 47 KB) |
| 687 | Inulin from Agave tequilana | GRN 687 (PDF 16.5 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 54 KB) |
| 686 | Curcumin from turmeric (Curcuma longa L.) | GRN 686 (PDF 5.2 MB) |
FDA has no questions (PDF 152 KB) |
| 685 | Lactobacillus plantarum strain 299v | GRN 685 (PDF 4.8 MB) |
FDA has no questions (PDF 44 KB) |
| 684 | Mung bean protein isolate | GRN 684 (PDF 8.3 MB) |
FDA has no questions (PDF 119 KB) |
| 683 | Canola protein isolate | GRN 683 (PDF 13.6 MB) |
FDA has no questions (PDF 75 KB) |
| 682 | Lecithin from canola | GRN 682 (PDF 7.2 MB) |
FDA has no questions (PDF 151 KB) |
| 681 | Dried isomaltulose syrup | GRN 681 (PDF 7.3 MB) |
FDA has no questions (PDF 151 KB) |
| 680 | Alpha-L-arabinofuranosidase from Talaromyces pinophilus produced by Trichoderma reesei | GRN 680 (PDF 639 kB) |
FDA has no questions (PDF 101 KB) |
| 679 | Dealcoholized fermented orange juice | GRN 679 (PDF 2.2 MB) |
FDA has no questions (PDF 67 KB) |
| 678 | Alpha-cyclodextrin | GRN 678 with Amendments (PDF 9.4 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 49 KB) |
| 677 | Docosahexaenoic acid oil produced in Schizochytrium sp. | GRN 677 (PDF 12.3 MB) |
FDA has no questions (PDF 101 KB) |
| 676 | Colicin | GRN 676 (PDF 1.9 MB) |
FDA has no questions (PDF 90 KB) |
| 675 | Xylanase enzyme preparation produced by Trichoderma reesei carrying a xylanase gene from Talaromyces leycettanus | GRN 675 (PDF 776 kB) |
FDA has no questions (PDF 76 KB) |
| 674 | Isomalto-oligosaccharides | GRN 674 (PDF 1.2 MB) |
FDA has no questions (PDF 160 KB) |
| 673 | Algal fat derived from Prototheca moriformis (S7737) | GRN 673 (PDF 15.3 MB) |
FDA has no questions (PDF 76 KB) |
| 672 | Preparation containing five bacterial monophages specific to Shigella spp. | GRN 672 (PDF 1.4 MB) |
FDA has no questions (PDF 109 KB) |
| 671 | Galacto-oligosaccharides (GOS) | GRN 671 (PDF 4 MB) |
At the notifier's request, FDA ceased to evaluate this notice (PDF 62 KB) |
| 670 | Inactivated Bacillus coagulans GBI-30, 6086 | GRN 670 (PDF 325 KB) |
FDA has no questions (PDF 47 KB) |
| 669 | Cow's milk-derived lactoferrin | GRN 669 Part 1 (PDF 9.4 MB) GRN 669 Part 2 (PDF 18.3 MB) GRN 669 Part 3 (PDF 9.8 MB) GRN 669 Part 4 (PDF 14.3 MB) |
FDA has no questions (PDF 168 KB) |
| 668 | Sodium formate | GRN 668 (PDF 2.6 MB) |
FDA has no questions (PDF 106 KB) |
| 667 | Rebaudioside M | GRN 667 (PDF 6.5 MB) |
FDA has no questions (PDF 115 KB) |
| 666 | Chondroitin sodium sulfate | GRN 666 (PDF 4.9 MB) |
FDA has no questions (PDF 109 KB) |
| 665 | Lactoperoxidase system | GRN 665 (PDF 658 kB) |
At the notifier's request, FDA ceased to evaluate this notice |
| 664 | Alpha-amylase from Cytophaga sp. expressed in Bacillus licheniformis | GRN 664 (PDF 1 MB) |
FDA has no questions (PDF 79 KB) |
| 663 | Distarch phosphate | GRN 663 (PDF 2.6 MB) |
At the notifier's request, FDA ceased to evaluate this notice |
| 662 | Glucosylated steviol glycosides (minimum purity 95%) | GRN 662 (PDF 5.9 MB) |
FDA has no questions |
| 661 | Fucus vesiculosus concentrate | GRN 661 (PDF 9.7 MB) |
FDA has no questions (PDF 85 KB) |
| 660 | Bacillus coagulans GBI-30, 6086 | GRN 660 (PDF 3.6 MB) |
FDA has no questions (PDF 81 KB) |
| 659 | Lacto-N-neotetraose | GRN 659 with Supplement (PDF 3.3 MB) |
FDA has no questions Supplemental Response Letter (PDF 267 KB) |
| 658 | Grapefruit extract | At the notifier's request, FDA ceased to evaluate this notice | |
| 657 | Glucoamylase from Penicillum oxalicum produced in Aspergillus niger | FDA has no questions | |
| 656 | Enzyme-modified steviol glycosides |
Supplemental Response Letter |
|
| 655 | Rice bran wax | At the notifier's request, FDA ceased to evaluate this notice | |
| 654 | Cocoa butter substitute | FDA has no questions | |
| 653 | Lysophospholipase from Aspergillus nishimurae expressed in Trichoderma reesei. | FDA has no questions | |
| 652 | Gamma linolenic acid safflower oil | GRN 652 with Amendments (PDF 3.4 MB |
FDA has no questions |
| 651 | Phospholipase A1 from Talaromyces leycettanus produced in Aspergillus niger | FDA has no questions | |
| 650 | 2'-O-fucosyllactose |
Supplemental Response Letter Supplemental Response Letter 2 |
|
| 649 | β-galactosidase enzyme preparation from Bacillus circulans produced in Bacillus subtilis | FDA has no questions | |
| 648 | Monoglycerides | FDA has no questions | |
| 647 | D-psicose | At the notifier's request, FDA ceased to evaluate this notice | |
| 646 | Pecan shell fiber | FDA has no questions | |
| 645 | Pullulanase from Bacillus deramificans and Bacillus acidopullulyticus expressed in Bacillus licheniformis | FDA has no questions | |
| 644 | Non-fat dry goat milk and goat whey protein | FDA has no questions | |
| 643 | Phosphatidylserine derived from fish | At the notifier's request, FDA ceased to evaluate this notice | |
| 642 | Camelina oil | FDA has no questions | |
| 641 | Pyrroloquinoline quinone disodium salt | FDA has no questions | |
| 640 | Esterified propoxylated glycerol | FDA has no questions | |
| 639 | Zeaxanthin from marigold | FDA has no questions | |
| 638 | High purity steviol glycosides (minimum purity 97%) consisting primarily of rebaudioside A | FDA has no questions | |
| 637 | Phosphatidylserine derived soy lecithin | At the notifier's request, FDA ceased to evaluate this notice | |
| 636 | Phosphatidylserine derived from sunflower | At the notifier's request, FDA ceased to evaluate this notice | |
| 635 | Nicotinamide riboside chloride | FDA has no questions | |
| 634 | Calcium chloride | FDA has no questions | |
| 633 | Whey protein | FDA has no questions | |
| 632 | Rebaudioside A from Yarrowia lipolytica | FDA has no questions | |
| 631 | Triacylglycerol lipase from Fusarium oxysporum produced in Trichoderma reesei | FDA has no questions | |
| 630 | Preparation containing the bacterial monophages, Fo1a and S16, specific to Salmonella | At the notifier's request, FDA ceased to evaluate this notice | |
| 629 | Siraitia grosvenorii Swingle (Luo Han Guo) fruit extract | At the notifier's request, FDA ceased to evaluate this notice | |
| 628 | endo-1,4-beta-xylanase from Trichoderma reesei | FDA has no questions | |
| 627 | Siraitia grosvenorii Swingle (Luo Han Guo) fruit juice concentrate | FDA has no further questions | |
| 626 | Steviol glycosides produced in Saccharomyces cerevisiae | FDA has no questions | |
| 625 | Pyrroloquinoline quinone disodium salt | FDA has no questions | |
| 624 | D-allulose 3-epimerase from Arthrobacter globiformis M30 produced in Escherichia coli | FDA has no questions | |
| 623 | Fructooligosaccharides | FDA has no questions | |
| 622 | Emulsified fish oil | At the notifier's request, FDA ceased to evaluate this notice | |
| 621 | Emulsified algal oil | At the notifier's request, FDA ceased to evaluate this notice | |
| 620 | Galacto-oligosaccharides | FDA has no questions | |
| 619 | Purified steviol glycosides | FDA has no questions | |
| 618 | Purified seawater | FDA has no questions | |
| 617 | α-amylase from Cytophaga sp. produced in Bacillus licheniformis | At the notifier's request, FDA ceased to evaluate this notice | |
| 616 | High-amylose cornstarch acetate | FDA has no questions | |
| 615 | High-amylose cornstarch | FDA has no questions | |
| 614 | Chromium polynicotinate | FDA has no questions | |
| 613 | Apple peel powder | At the notifier's request, FDA ceased to evaluate this notice | |
| 612 | Fractionated whey protein isolate containing cow’s milk derived lactoferrin, lactoperoxidase, and transforming growth factor β2 | At the notifier's request, FDA ceased to evaluate this notice | |
| 611 | Fractionated whey protein isolate containing cow’s milk derived lactoferrin, lactoperoxidase, and transforming growth factor β2 | At notifier's request, FDA ceased to evaluate the notice | |
| 610 | Isomaltodextrin |
FDA has no questions
|
|
| 609 | Rice protein | Additional letter (PDF 81 KB) FDA has no questions |
|
| 608 | Pea protein concentrate | FDA has no questions | |
| 607 | Glucosylated steviol glycosides (minimum purity 80%) |
Supplemental letter |
|
| 606 | Vinyl acetate-vinyl laurate copolymers | FDA has no questions | |
| 605 | Fructo-oligosaccharides | FDA has no questions | |
| 604 | Baker's Yeast (Saccharomyces cerevisiae) expressing asparaginase II | FDA has no questions | |
| 603 | Preparation containing the bacterial monophages, BP-63 and BP-12, specific to Salmonella | FDA has no questions | |
| 602 | N-acetyl-D-neuraminic acid | FDA has no questions | |
| 601 | Bacillus coagulans SBC37-01 spore preparation | FDA has no questions | |
| 600 | Hydroxytyrosol | FDA has no questions | |
| 599 | Citrus fiber | FDA has no questions | |
| 598 | Thermolysin enzyme preparation derived from Geobacillus stearothermophilus | FDA has no questions | |
| 597 | Bacillus coagulans SNZ1969 spores preparation | FDA has no questions | |
| 596 | Breadfruit flour | FDA has no questions | |
| 595 | gamma-aminobutyric acid |
At the notifier's request, FDA ceased to evaluate this notice |
|
| 594 | α-amylase from Geobacillus stearothermophilus produced in Bacillus licheniformis | FDA has no questions | |
| 593 | Colicin preparations | FDA has no questions | |
| 592 | β-glucanase from Bacillus subtilis | FDA has no questions | |
| 591 | Streptococcus salivarius K12 | GRN 591 (PDF 1.92 MB) |
FDA has no questions |
| 590 | Pyrroloquinoline quinone | At the notifier's request, FDA ceased to evaluate this notice | |
| 589 | Xylanase from Aspergillus niger | FDA has no questions | |
| 588 | Zeaxanthin from Capsicum annum (paprika) | FDA has no questions; some uses may require a color additive listing | |
| 587 | Acetolate decaroxylase from Bacillus brevis produced in Bacillus licheniformis | FDA has no questions | |
| 586 | Taurine | FDA has no questions | |
| 585 | 1-methylcyclopropene | FDA has no questions | |
| 584 | Cellulase from Penicillium funiculosum | FDA has no questions | |
| 583 | Esterified propoxylated glycerol | FDA has no questions | |
| 571 | 2'-Fucosyllactose | Supplemental Response Letter (PDF 209 kB) |
|
| 468 | Preparation containing the bacterial monophages, Fo1a and S16, specific to Salmonella | Supplemental Response Letter (PDF 98.08 KB) |
|
| 452 | Enzyme-modified steviol glycosides | Additional Correspondence (PDF 282 KB) |
|
| 435 | Preparation consisting of six bacterial monophage specific to Salmonella enterica (monophage cocktail) |
Supplemental Letter
|
|
| 399 | Preparation of Bacillus coagulans strain GBI-30, 6086 spores | GRN 399 with Amendments (PDF 1.2 MB) |
|
| 379 | Tuna oil | GRN 379 with Amendments (PDF 6.5 MB) |
|
| 229 | Methylsulfonylmethane | Additional correspondence (PDF 45 KB) |
|
| 183 | Phospholipase A2 enzyme preparation from Aspergillus niger expressing a gene encoding a porcine phospholipase A2 | Additional correspondence (PDF 46 KB) |
|
| 091 | Mycoprotein | Additional correspondence (PDF 110 KB) |